

Dexxon Holdings Inc.: Private Company Information - Bloomberg








































  





















































































July 28, 2017 9:14 AM ET

Company Overview of Dexxon Holdings Inc.



Snapshot People




Company Overview
Dexxon Holdings Inc. is based in Canada.


,  Canada










Key Executives for Dexxon Holdings Inc.


Dexxon Holdings Inc. does not have any Key Executives recorded. 





Similar Private Companies By Industry



Company Name
Region



 #20 Seabright Holdings Ltd. Americas 'Osram Lighting Ltd Americas (c.C.A.) Commercial Credit Adjusters Ltd Americas (Ysw) Yacht Sales West Incorporated Americas /n Spro Inc. Americas




Recent Private Companies Transactions



TypeDate
Target





Merger/Acquisition

			      August 31, 2016
			    
Cynapsus Therapeutics Inc.





Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States The Advertising Council, Inc. United States Bertelsmann AG Europe Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Dexxon Holdings Inc., please visit --.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close




























Dexxon Holdings Ltd.: Private Company Information - Bloomberg








































  





















































































July 28, 2017 9:14 AM ET

Company Overview of Dexxon Holdings Ltd.



Snapshot People




Company Overview
Dexxon Holdings Ltd. is based in Hadera, Israel.


South Ind. ZoneOr AkivaP.O. Box 50Hadera,  38100Israel



Phone: 972 4 636 4000








Key Executives for Dexxon Holdings Ltd.


Dexxon Holdings Ltd. does not have any Key Executives recorded. 





Similar Private Companies By Industry



Company Name
Region



 (BY) Medimor Ltd. Middle East/Africa 05PC, Ltd. Middle East/Africa 1 Global Digital Distribution Limited Ltd Middle East/Africa 101 International Economic Consulting Ltd. Middle East/Africa 10bis.Co.Il Ltd. Middle East/Africa




Recent Private Companies Transactions



TypeDate
Target



No transactions available in the past 12 months.




Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States The Advertising Council, Inc. United States Bertelsmann AG Europe Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Dexxon Holdings Ltd., please visit --.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Home - Dexcel



















































 














PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

View Dexcel's vision





Novel OTC formulation

Novel Formulation of a well-known US OTC Brand







Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC







Complex Injectable(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma







ViePax® XR(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules





















Bringing creativity to world markets

Dexcel Pharma® is synonymous with innovation. We excel at identifying opportunities and patient needs and then developing and commercializing real value-add products. Where others see obstacles, we see opportunities.

Read More




Strong, long-lasting partnership

We continue to build our growing international network of quality partners, and look forward to uniting with new partners for future success
 

Read More




Driven by Innovation

Dexcel Pharma® strives to meet the unmet needs of patients by applying innovative R&D in all areas of the Pharma value chain and exploiting unique capabilities with complex formulations and sophisticated regulatory strategies

Read More




Quality from start to finish

All Dexcel Pharma® sites deploy state-of-the-art equipment and are highly automated to ensure uncompromising quality

Read More




Global Reach

Dexcel Pharma® is a truly global enterprise, with over 80% of sales generated abroad. We are committed to long-term growth, entering new markets and constantly enhancing our product line

Read More






R&D

Dexcel Pharma is focused on the development of novel and proprietary formulations of existing  molecules and high complexity generic formulations

Read More


Capabilities

We believe that strong manufacturing capabilities are part of our core business. All our sites use state of the art equipment and are highly automated in order to ensure the highest level of quality

Read More





Pipeline


Product
Therapeutic area

Development Stage

Preclinical / Formulation
Clinical Development
Registration


Expected Launch







									   			Undisclosed									    	



OTC






2017






									   			Undisclosed									    	



OTC






2017






PerioChip®(New indication) 



Dental






2018






									   			Undisclosed									    	



Ophthalmology






2020



Full Pipeline




Success

All Products









Omeprazole Delayed Released Tablet

Dexcel Pharma’s proprietary formulation of Omeprazole 20mg Delayed Release tablet was launched in March 2008 as the first OTC store brand equivalent to Prilosec OTC®. This high quality, value saving alternative has been the market leader since launch.
Through an exclusive partnership with Perrigo, Dexcel’s Omeprazole OTC is sold in nearly every pharmacy chain across the US. The product continues to gain market share and produce year-over-year growth despite increased competition from new molecules hitting the OTC shelves.
In 2015, Dexcel’s Widlberry Mint Omeprazole OTC tablets were launched as an addition to the product line.

Read More

 


PerioChip®(Chlorhexidine Gluconate)

PerioChip® is an innovative, easy to apply, biodegradable chip containing 2.5 mg of chlorhexidine gluconate – a non antibiotic adjunct treatment to scaling and root planing (SRP) and is ideal for reducing pocket depth in patients with adult periodontitis.
PerioChip® is clinically effective and well tolerated in the treatment of periodontal pockets with depth of 5 mm and more. 
Since launch, millions of chips have been administered by dental professionals across the globe, and our strong commitment to working closely with doctors and clinics helps them adopt PerioChip® into their practices as 1st line treatment for long-term growth.
PerioChip is manufactured in Israel and sold successfully in various countries around Europe, USA, Israel and the Asia- Pacific region.

Read More

 


Deximune® (Ciclosporin)

The Dexcel Pharma team of formulation experts developed Deximune® – a soft-gelatin capsule formulation bio-equivalent to Neoral®.
Deximune® is an immunosuppressant used following transplants and in the field of Dermatology.
Deximune® is licensed for all Ciclosporin indications and is sold in various European countries, Israel & Singapore.

Read More

 






A career at Dexcel

At Dexcel the success of our company and its employees are one. Excellence and professionalism prevail in everything we do. If you believe in creating a work environment where customers and employees are at all times equally valued and highly respected, and where fairness, teamwork and success abound, then we invite you to submit an application to work with us.

Read More






Strategic Investments












Roivant Sciences

Roivant Sciences is a unique biopharmaceutical firm dedicated to realizing the full value of promising drug candidates by advancing them from late-stage clinical development to commercialization.


Read More






Cynapsus Therapeutics

Cynapsus is a clinical-stage, specialty pharmaceutical company developing a convenient and easy to use sublingual thin film strip to manage OFF episodes associated with Parkinson’s disease.


Read More






Dexcel Worldwide




Read More









United Kingdom
Dexcel Pharma Ltd.
7 Sopwith Way,
Drayton Fields Daventry, UK
Northamptonshire NN11 8PB
T. +44 (0)1327 312 266
E. office@dexcel.com






Israel
Corporate Headquarters
1 Dexcel St., Or Akiva, 30600000, Israel
T. +972 (0) 4 636 4000
F. +972 (0) 4 636 4004
E. info@dexcel.com
W. www.dexcel.com






Germany
Dexcel Pharma GmbH
Carl-Zeiss-Straße 2, D-63755 Alzenau
T. +49 (0) 6023 94800
E. service@dexcel.com
W. www.dexcel-pharma.de






















































 




























 





Ethics & Business Conduct - Dexcel


















































 














PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

View Dexcel's vision





Novel OTC formulation

Novel Formulation of a well-known US OTC Brand







Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC







Complex Injectable(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma







ViePax® XR(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules













Profile



Dexcel In Numbers



History



Worldwide



Executive Team



Strategic Investments



Events



Business Ethics

 Ethics & Business Conduct






Dexcel Pharma readily affirms its commitment to maintaining the highest standards of ethical conduct and strict compliance with the guidelines, rules, and regulations that govern our business practices. Our core values – integrity, ethical behavior, commitment to quality, and professionalism – demonstrate our pledge to excel in every aspect of our business.
 
As part of this commitment, Dexcel Pharma has established certain principles designed to guide employees and business partners in their business-related actions to avoid potential misconduct, including a complete ban on exerting any kind of bribery or improper influence in any type of business transaction.
 
Additionally, Dexcel Pharma recognizes that human trafficking is a serious crime and a grave violation of human rights, and has adopted policies to combat human trafficking in its supply chain, including requiring the inclusion of an appropriate anti-human trafficking clause in relevant supply chain agreements.
 
Dexcel Pharma expects all of its employees and business partners to conduct themselves in compliance with both their legal and ethical responsibilities in all daily business operations. Dexcel Pharma is unreservedly committed to the foregoing and will forgo any business transactions that would violate it.
 
Dexcel Pharma’s Risk Assessment Committee will periodically assess the group’s effectiveness in ensuring that bribery and human trafficking are not taking place in its business or supply chains.
 
We look forward to working with our business partners in a manner which will allow us to demonstrate our commitment to our principles of ethical behavior and our record as an excellent corporate citizen.



 




















Recruitment - Dexcel




















































 














PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

View Dexcel's vision





Novel OTC formulation

Novel Formulation of a well-known US OTC Brand







Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC







Complex Injectable(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma







ViePax® XR(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules













Careers



Recruitment



Jobs

 Recruitment





How to apply
To apply for a position at Dexcel, please send your resume using the link on the open positions page. Resumes are reviewed by the recruitment coordinator. If it is determined that you are a potential candidate for the position, you will hear from the Recruitment Coordinator, who will conduct a preliminary telephone interview. This interview will cover your experience, and the details of the position. Candidates who pass this stage are invited for a frontal interview. 



 




















Dexcel Worldwide - Dexcel




















































 














PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

View Dexcel's vision





Novel OTC formulation

Novel Formulation of a well-known US OTC Brand







Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC







Complex Injectable(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma







ViePax® XR(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules













Profile



Dexcel In Numbers



History



Worldwide



Executive Team



Strategic Investments



Events



Business Ethics

 Dexcel Worldwide
We are committed to long-term growth, entering new markets and constantly enhancing our product line. Operating throughout the world makes us more responsive, helps us to identify opportunities and understand the challenges in the markets where our products are sold. Today, approximately 80% of our revenues are generated outside of Israel, making Dexcel a truly global enterprise.













United Kingdom
Dexcel Pharma Ltd.
7 Sopwith Way,
Drayton Fields Daventry, UK
Northamptonshire NN11 8PB
T. +44 (0)1327 312 266
E. office@dexcel.com






Israel
Corporate Headquarters
1 Dexcel St., Or Akiva, 30600000, Israel
T. +972 (0) 4 636 4000
F. +972 (0) 4 636 4004
E. info@dexcel.com
W. www.dexcel.com






Germany
Dexcel Pharma GmbH
Carl-Zeiss-Straße 2, D-63755 Alzenau
T. +49 (0) 6023 94800
E. service@dexcel.com
W. www.dexcel-pharma.de























































Israel Corporate Headquarters

1 Dexcel St., Or Akiva, 30600000, Israel
T. +972 (0) 4 636 4000
F. +972 (0) 4 636 4004
E. info@dexcel.com  w. www.dexcel.com




U.K Dexcel Pharma Ltd.

7 Sopwith Way, Drayton Fields Daventry,
Northamptonshire NN11 8PB UK
T. +44 (0)1327 312 266
E. office@dexcel.com



Germany Dexcel Pharma GmbH

Carl-Zeiss-Straße 2, D-63755 Alzenau
T. +49 (0) 6023 94800
E. service@dexcel.com
W. www.dexcel-pharma.de









Dexcel Network
Dexcel offers a range of value added branded and generic products through a global network of subsidiaries, distributors and partners in over 30 markets. We utilize dual commercial models for branded and generic  products, operate targeted sales forces to physicians and deploy a range of sales strategies suited to specific products and territories. Dexcel’s products are promoted by specialty salesforces supporting flagship products, such as PerioChip®. Our state of the art manufacturing capabilities allow us to be among the top suppliers of generics in Western Europe, including Germany and the UK. We are eager to expand into new markets. For information on joining the Dexcel global network, please Contact us.



 




















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft











Dexxon Holdings Ltd. - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Dexxon Holdings Ltd.
Check out list of companies and businesses related to Dexxon Holdings Ltd.. Find out Dexxon Holdings Ltd. address and contact details. View other people related to Dexxon Holdings Ltd. - coworkers, colleagues, companions, etc.
Address:   

1 DEXCEL STREET  OR AKIVA 30600000 Israel




Companies related to Dexxon Holdings Ltd.
CIKCompany NamePositionCompany Address0001447028Arbutus Biopharma Corp100-8900 GLENLYON PARKWAY  BURNABY V5J 5J80001636050Axovant Sciences Ltd.20-22 BEDFORD ROW  LONDON WC1R 4JS0001679082Myovant Sciences Ltd.20-22 BEDFORD ROW  LONDON WC1R 4JS




Dexxon Holdings Ltd. on the Web
Persons related to Dexxon Holdings Ltd. - Arbutus Biopharma CorpNamePositionCityMichael J.  AbramsManaging Director BURNABYPaul A.  BrennanBURNABYDANIEL D  BURGESSDirector SAN DIEGOHERBERT J  CONRADDirector MIDDLETONBruce  CousinsEVP & Chief Financial Officer BURNABYJEWELL  DONALDBURNABYARTHUR  BRUSKIN  DR.BURNABYIAN  MACLACHLAN  DR.BURNABYMARK  MURRAY  DR.BURNABYMICHAEL  ABRAMS  DR.BURNABYDiane  GardinerBURNABYFRASHIER  GARYBURNABYOLE ANDREAS  HALVORSENGREENWICHRICHARD C  HENRIQUES JRDirector WHITEHOUSE STATIONRICHARD C  HENRIQUES JRBURNABYPatrick T.  HigginsBURNABYElizabeth  HowardExec. VP & General Counsel BURNABYMORTIMER  IANBURNABYHUDSON  JAMESBURNABYDonald Gordon  JewellBURNABYFRANK  KARBEDirector SOUTH SAN FRANCISCOFRANK  KARBEBURNABYDANIEL L  KISNERSAN DIEGODANIEL L  KISNERBURNABYMark  KowalskiSr VP & Chief Medical Officer BURNABYAndrew  LoHAMILTONPeter  LutwycheChief Technology Officer BURNABYClarence Patrick  MachadoSAN FRANCISCOKEITH S  MANCHESTERDirector FORREST  MICHAELBURNABYMark J.  MurrayPresident & CEO BURNABYDan  OrenOR AKIVADavid C.  OttGREENWICHPeggy V  PhillipsBERKELEYPeggy V  PhillipsBURNABYQVT Associates GP LLCNEW YORKQVT Fund V LPNEW YORKIAN  LENNOX  R.BURNABYVivek  RamaswamyDirector BURNABYRoivant Sciences Ltd.HAMILTONRose Sharon  ShabetGREENWICHMichael J.  SofiaChief Scientific Officer BURNABYDaniel S.  SundheimGREENWICHWilliam T.  SymondsChief Development Officer BURNABYVGE III Portfolio Ltd.GREENWICHViking Global Equities II LPGREENWICHViking Global Equities LPGREENWICHVIKING GLOBAL INVESTORS LPGREENWICHViking Global Opportunities GP LLCGREENWICHViking Global Opportunities Illiquid Investments Sub-Master LPGREENWICHViking Global Opportunities Portfolio GP LLCGREENWICHVIKING GLOBAL PERFORMANCE LLCGREENWICHViking Long Fund GP LLCGREENWICHViking Long Fund Master Ltd.GREENWICHPersons related to Dexxon Holdings Ltd. - Axovant Sciences Ltd.NamePositionCityMichael  AdasczikPrincipal Accounting Officer NEW YORKMark  AltmeyerPres (ASG) & Chief Comm. Ofc. NEW YORKChristine Mikail  CvijicChief Admin Officer and GC SEATTLEKATHRYN E  FALBERGDirector ROCKVILLELAWRENCE MD PHD  FRIEDHOFFChief Development Officer NEW YORKOLE ANDREAS  HALVORSENGREENWICHDavid  HungPrincipal Executive Officer SAN FRANCISCOAndrew  LoHAMILTONClarence Patrick  MachadoDirector SAN FRANCISCOMarion  McCourtPrincipal Operating Officer SAN FRANCISCOBerndt  ModigDirector NEW YORKStephen Frederick  MohrGeneral Counsel NEW YORKLAWRENCE S  OLANOFFDirector NEW YORKDan  OrenOR AKIVAIlan  OrenNEW YORKDavid C.  OttGREENWICHAtul  PandeDirector NEW YORKGary P.  PisanoDirector NEW YORKQVT Associates GP LLCNEW YORKQVT Fund V LPNEW YORKVivek  RamaswamyPrincipal Executive Officer BURNABYAlan S.  RoemerNEW YORKRoivant Sciences Ltd.HAMILTONMarianne L.  RomeoHead,Global Trans & Risk Mgmt HAMILTONRose Sharon  ShabetGREENWICHDaniel S.  SundheimGREENWICHW ANTHONY  VERNONDirector SAN FRANCISCOVGE III Portfolio Ltd.GREENWICHViking Global Equities II LPGREENWICHViking Global Equities LPGREENWICHVIKING GLOBAL INVESTORS LPGREENWICHViking Global Opportunities GP LLCGREENWICHViking Global Opportunities Illiquid Investments Sub-Master LPGREENWICHViking Global Opportunities Portfolio GP LLCGREENWICHVIKING GLOBAL PERFORMANCE LLCGREENWICHViking Long Fund GP LLCGREENWICHViking Long Fund Master Ltd.GREENWICHGregory M  WeinhoffPrincipal Financial Officer STAMFORDPersons related to Dexxon Holdings Ltd. - Myovant Sciences Ltd.NamePositionCityMark  AltmeyerDirector NEW YORKTerrie  CurranDirector NEW YORKWayne S  DeVeydtDirector INDIANAPOLISOLE ANDREAS  HALVORSENGREENWICHFRANK  KARBESOUTH SAN FRANCISCOMatthew  LangGeneral Counsel & Corp. Secy. BRISBANEAndrew  LoHAMILTONClarence Patrick  MachadoSAN FRANCISCOKEITH S  MANCHESTERDan  OrenOR AKIVADavid C.  OttGREENWICHQVT Associates GP LLCNEW YORKQVT Fund V LPNEW YORKVivek  RamaswamyBURNABYRoivant Sciences Ltd.HAMILTONMarianne L.  RomeoHAMILTONKathleen  SebeliusDirector MENLO PARKLynn  SeelyPrincipal Executive Officer SAN FRANCISCORose Sharon  ShabetGREENWICHDaniel S.  SundheimGREENWICHPharmaceuticals International AG  Takeda10% Owner ZURICHVGE III Portfolio Ltd.GREENWICHViking Global Equities II LPGREENWICHViking Global Equities LPGREENWICHVIKING GLOBAL INVESTORS LPGREENWICHViking Global Opportunities GP LLCGREENWICHViking Global Opportunities Illiquid Investments Sub-Master LPGREENWICHViking Global Opportunities Portfolio GP LLCGREENWICHVIKING GLOBAL PERFORMANCE LLCGREENWICHViking Long Fund GP LLCGREENWICHViking Long Fund Master Ltd.GREENWICH












 









Capabilities - Dexcel




















































 














PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

View Dexcel's vision





Novel OTC formulation

Novel Formulation of a well-known US OTC Brand







Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC







Complex Injectable(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma







ViePax® XR(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules











Capabilities
At Dexcel, we believe that strong manufacturing capabilities are part
of our core business. All our sites use state of the art equipment and
are highly automated in order to ensure the highest level of quality.
 
Dexcel manufacturing facilities employ cutting-edge,
computer-controlled technologies, including electronic batch
recording, automated warehousing, end of line automation and more.
This facilitates optimization of production and reduces human error.
 
Our global supply chain management and responsive service ensure
consistency, competitive pricing, timely delivery and efficient
inventory control.






Quality
All our production sites are approved by the FDA and EMA and are operating according to cGMP standards.
We enjoy an excellent track record with regulatory authorities, partners, and customers.



Manufacturing Capabilities
Dexcel specializes in the manufacturing of modified release Oral Solid Dosage products. Our facilities operate 24 hours a day and have a combined manufacturing capacity of over 5 billion units per year.








Manufacturing and R&D Sites Yokneam
Our bulk manufacturing site in
Yokneam is highly automated and was
specially designed for efficient
manufacturing of high volume products.








Or Akiva
Our campus in Or Akiva is designed for mid volume products, including state of the art packaging and QC facilities. Dexcel’s headquarters are located in Or Akiva.








Jerusalem
Our Jerusalem site is designed for the
production of low volume, specialty
products and also serves as an R&D center.
No manufacturing in Jerusalem to date.







 




















Events - Dexcel


















































 














PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

View Dexcel's vision





Novel OTC formulation

Novel Formulation of a well-known US OTC Brand







Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC







Complex Injectable(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma







ViePax® XR(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules













Profile



Dexcel In Numbers



History



Worldwide



Executive Team



Strategic Investments



Events



Business Ethics

 Events





Past Events




April 08-10, 2016 / Singapore
IDEM
Continues to play a strategic role for exhibitors in the dental industry by facilitating development and outreach into the highly dynamic Asia-Pacific region. Join us  to discover the latest innovations and trends in dentistry





view website








September 2015 / Kiev
MEDVIN
Top event for Ukrainian dental sector. It presents existing brands and new players of country’s dental market. The 68th International Dental Scientific Forum will take place during the event. 





view website






















February 2015 / Cologne, Germany
IDS
Visit us at the top event for the international dental sector. IDS 2015 will present the entire range of products available and brings together all relevant target groups from the worldwide dental sector.





view website


















June 03, 2015 / Stand 24 Capital Hall
EUROPERIO 8
Visit us in London at the Europerio Congress, the world’s leading conference in periodontology and implant dentistry and the essential triennial fixture on the meetings calendar.



















 




















Send CV - Dexcel


















































 














PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

View Dexcel's vision





Novel OTC formulation

Novel Formulation of a well-known US OTC Brand







Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC







Complex Injectable(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma







ViePax® XR(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules













Careers



Recruitment



Jobs

 Send CV





THANK YOU
Your message was sent successfully


* Required field
Fill out the details to apply for the job





















*Choose a subjectGeneral
Browse

*Upload CV






 

Dexcel Pharma does not have any operations in nor any opportunities for internships or employment in the United States. If you have received an unsolicited offer of employment or have responded to an online job posting promising employment with Dexcel Pharma in the United States, we suggest that you contact your local police or the FBI through its Internet Crime Complaint Center website www.ic3.gov/default.aspx






 























DEXXON HOLDINGS LTD, Business Services in OR AKIVA - dun'sguide







































Dun'sGuide
Israel's Business Guide






 eng 


 eng 


 עבר 






Connect




Connect

Full name





Forgot your password?
Register




Forgot your password?
Register




To reset password  please enter your email
















New password has been sent
Log In












Search by

Business field

Name of Business

Enter Keyword for Search
Region not found







Create your business page






Homepage
Business Services
Business services
Sharon Area
OR AKIVA
DEXXON HOLDINGS LTD





DEXXON HOLDINGS LTD
דקסון אחזקות בע"מ
  


Call
Order D&B Report

Claim your business



 +    

Add to Favorites








Also known as



Hebrew Name
דקסון אחזקות בע"מ


Phone Number
+972-4-6364000


Fax Number
+972-4-6364004


Mailing Address
1, OR AKIVA 3060000


Opening Hours



Languages



Service Areas



Report an error





















Fields of Activity



Marketing and business consulting


Business Services


Management and maintenance of properties


Medical equipment


Medicines


Pharmacies



Specialty



Business services


Holding companies


Proprietary medicines











Business Data

View more details







More businesses related to Business Services  



 D&B's Credibility Mark is a seal of approval designed to reflect a level of business credibility and ease a consumer's decision making process as they move towards a business transaction. This stamp is based on our professional opinion and on the information we have as to the quality levels of the products or services offered.




















Call









   Facebook  
    Twitter  
    +Google  
    linkedin  
   Email  





+ 


 
Established: 









Selected Business Services businesses around you












Established: 



  




Real Estate & Construction



High tech & Computing services



Engineering & Architecture Businesses Interior Design



Law Firms



Accounting Firms



Additional Fields





All you need to know about businesses in Israel and worldwide
Before engaging in any business relationship, you should gather as much information as you can regarding who you seek to get involved with. That is exactly why we exist. We provide an extensive database that will show you everything you need to know about other businesses and companies, so that you will be able to make informed decisions before committing.








Locate Potential Customers
How financially stable the business you're interested in actually is. Is this business connection an unnecessary risk or a golden opportunity? This elaborate report was designed by our specialists, based on the questioning of interested parties, business environment analysis and professional risk assessment.
View Demo









Ownership Structure
Ownership percentages, parent companies, subsidiaries, executives... You'll find it all here. Through this dynamic system, featuring information on ownership ties, cross-holdings and risk rates, you can have a clearer image of the company in question from a legal, business and personal perspective.
View Demo









Cross-referencing Business Data
"Show me your friends and I'll tell you who you are" is an accurate saying for the business world as well. That is why we created a special report that examines business ties, thus reflecting potential risks or opportunities within business relationships.
View Demo









Business Information and Credit Risk Management Report
Knowledge is power, and we have quite a lot of it when it comes to demographics targeted down to the finest detail. Here you can find new audiences for your business to generate additional growth.
View Demo









Locate Potential Customers





Ownership Structure





Cross-referencing Business Data





Business Information and Credit Risk Management Report








Sign up to dunsguide and enjoy



Full name





* mandatory field



I accept the site's term of use




I agree to receive promotional content

Already registered?Log In Now





Registration Complete
Continue to site








If you wish to purchase one of our products or services please contact us.










Business Information and Credit Risk Management Report
Cross-referencing Business Data
Ownership Structure
Locate Potential Customers





Contact a representative


 
or call  
03-7330480 



 
 שעות פעילות  
 Sun-Thu 09:00-18:00














Order D&B Report


Full name















 
or call  

03-7330480




 
 Opening Hours  
 Sun-Thu 09:00-18:00








Call
All you need to know about businesses in Israel and worldwide




Thank you for contacting us
Continue to site







Contact us DEXXON HOLDINGS LTD
























 
or call  

+972-4-6364000








Call





Thank you for contacting us
Continue to site







Report an error

















Business owner? Update your information here.
Contact us by phone: 03-5676754


Business owner? Update your information here.
Contact us by phone: 03-5676754
Call
or write to us




Thank you for contacting us
Continue to site







DEXXON HOLDINGS LTD






















Create your business page


Full name






>
>
>
>
>
* mandatory field





Thank you for contacting us
Continue to site









About dun'sguide
Advertise on dun'sguide
About D&B
About Credibility Mark
Information Solutions
Sign me up!
Dunsguide Blog
Contact Us


 D&B's Credibility Mark is a seal of approval designed to reflect a level of business credibility and ease a consumer's decision making process as they move towards a business transaction. This stamp is based on our professional opinion and on the information we have as to the quality levels of the products or services offered.









































DEXXON HOLDINGS LTD. Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      DEXXON HOLDINGS LTD.
                    

•   OR AKIVA, L3
                      
How do I update this listing?




                                             Dexxon Holdings Ltd. is based out of Or Akiva.    WhaleWisdom has at least 7 13D/G filings in our database for Dexxon Holdings Ltd..
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from DEXXON HOLDINGS LTD., enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




dexxon holdings ltd.


1 DEXCEL STREET

OR AKIVA
L3
                                                        
                                                    30600000


              Business Phone:
              972-4-636404







Recent SEC Filings




SC 13G filed on 02/13/2017
3 filed on 10/26/2016
SC 13D/A filed on 09/15/2016
SC 13D filed on 07/13/2016
SC 13D filed on 07/13/2016
3 filed on 07/13/2016
3 filed on 07/13/2016
SC 13D filed on 03/16/2016
SC 13D/A filed on 02/17/2016
3 filed on 06/10/2015











Current 13D/G Holdings


Stock
Sector
Shares Held
Market Value
Rank
Source
Source Date





Axovant Sciences Ltd (AXON)


      HEALTH CARE
    

      75,000,000
    

      980,250,000.00
    

      1
    

      13D
    

      2016-07-08
    



Myovant Sciences (MYOV)


      HEALTH CARE
    

      37,231,342
    

      463,157,894.48
    

      2
    

      13G
    

      2016-12-31
    



Arbutus Biophrm (ABUS)


      HEALTH CARE
    

      16,013,540
    

      62,612,941.40
    

      3
    

      13D
    

      2016-07-08
    



Cynapsus Therapeutics Inc (CYNA)


      HEALTH CARE
    

      2,725,199
    

      50,034,653.64
    

      4
    

      13D
    

      2016-08-31
    











Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free


































* :: Scrip

















In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way Informa uses cookies please go to our Cookie Policy page.






Scrip is part of the Business Intelligence Division of Informa PLC


Informa PLC


About us


Investor relations


Talent




This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.



                Informa
            








Toggle Menu

            Menu
        







 












Other Publications: In Vivo | Medtech Insight | Pink Sheet | Rose Sheet 










Register






                                    Sign In
                                





This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By  









                            UsernamePublicRestriction
                        




                Already Registered?
            

                Sign in to continue reading.
            



                Your login and/or password information does not match our records. Please try again.
            




Forgot your password?

 Remember Me
                    



Sign In










Thanks, we've sent a link to reset your password


Forgot your password?
 
Enter the email address associated with your account and an email will be sent to you to reset your password.
Please enter a valid email address.
Unfortunately we've not been able to process this request.




Submit




Need help?  Please call UK support at +44 (0)20 7017 4161 / US support at +1 617 374 2242 or onlineaccess@informa.com.





                New to Scrip?
            

                Request a free trial today! 

Free Trial


Register for our free email digests:
            



                        Your username does not meet the requirements.
                    

                        An account with that username already exists.
                    

                        Unfortunately we've not been able to process your registration. Please contact support.
                    

                        Register
                    














Toggle Menu

        Menu
    


Home







Commercial




Companies


Deals


Strategy


Market Access


Market Intelligence


Appointments









Research & Development




Clinical Trials


Approvals


Therapy Areas


Pipeline Watch






Policy & Regulation







                                            Hot Topics                                        



US Election 2016


Pricing Debate


Brexit






Regional Coverage




Meet the Team


Scrip Awards


Scrip 100


Scrip Asia 100


Ask The Analyst


PDF Library


RSS Feeds


Free Trial Request


Subscribe


Advertise















                UsernamePublicRestriction
            




                Already Registered?
            

                Sign in to continue reading.
            



                Your login and/or password information does not match our records. Please try again.
            




Forgot your password?

 Remember Me
                    



Sign In










Thanks, we've sent a link to reset your password


Forgot your password?
 
Enter the email address associated with your account and an email will be sent to you to reset your password.
Please enter a valid email address.
Unfortunately we've not been able to process this request.




Submit




Need help?  Please call UK support at +44 (0)20 7017 4161 / US support at +1 617 374 2242 or onlineaccess@informa.com.





                New to Scrip?
            

                Request a free trial today! 

Free Trial


Register for our free email digests:
            



                        Your username does not meet the requirements.
                    

                        An account with that username already exists.
                    

                        Unfortunately we've not been able to process your registration. Please contact support.
                    

                        Register
                    

















Email





Share





















Dexxon Ltd.




Latest From Dexxon Ltd.






                Bookmark
            









01 Apr 2002






            MediGus Ltd.
        




        MediGus Ltd. combines an endoscopic stapler with a miniaturized ultrasonic sighting system in a tool designed to permit surgeons to convert open or laparoscopic surgeries to least-invasive endoscopic surgeries.  
    


Medical Device


See All



Company Information

Industry

Pharmaceuticals             

 Drug Delivery             

 Controlled Release    




Therapeutic Areas
Non-Specific
Alias(es)
Ownership

Headquarters

Worldwide            

Middle East            

Israel            






Parent & Subsidiaries

Dexxon Ltd.


Dexcel Pharma Ltd.



Senior Management

            Dan  Oren, Managing Dir.Rafi  Lahav, Dir., R&DMati  Doron, Dir., Sales & Mktg.
        
Contact Info

Dexxon Ltd.
                Phone: (972) 4 571 252 
            1 Herzl Street, Tirat Hacarhel 
                        Haifa,  30200 
            Israel 






Advertisement







Advertisement



 









You must sign in to use this functionality



                Your login and/or password information does not match our records. Please try again.
            




Forgot your password?

 Remember Me
                    



Sign In










Thanks, we've sent a link to reset your password


Forgot your password?
 
Enter the email address associated with your account and an email will be sent to you to reset your password.
Please enter a valid email address.
Unfortunately we've not been able to process this request.




Submit




Need help?  Please call UK support at +44 (0)20 7017 4161 / US support at +1 617 374 2242 or onlineaccess@informa.com.














Authentication.SignIn.HeadSignInHeader



                Your login and/or password information does not match our records. Please try again.
            




Forgot your password?

 Remember Me
                    



Sign In










Thanks, we've sent a link to reset your password


Forgot your password?
 
Enter the email address associated with your account and an email will be sent to you to reset your password.
Please enter a valid email address.
Unfortunately we've not been able to process this request.




Submit




Need help?  Please call UK support at +44 (0)20 7017 4161 / US support at +1 617 374 2242 or onlineaccess@informa.com.











UsernamePublicRestriction
				

Register

Your username does not meet the requirements.
Sorry - this email domain is not allowed.
Sorry - public email accounts are not allowed. Please provide a work email address.
An account with that username already exists.
Unfortunately we've not been able to process your registration. Please contact support.

				Register
			





		Dexxon Ltd.
	








			Email Company
		




All set! This article has been sent to my@email.address.



				All fields are required. For multiple recipients, separate email addresses with a semicolon.
			


					Please make sure all fields are completed.
				

					Please enter a valid e-mail address
				


					Please make sure you have filled out all fields
				


					Please make sure you have filled out all fields
				


Subject: Dexxon Ltd.
                    



Add a personalized message to your email





Cancel


Send





				DCD.EmailPopout.Notice
			










×










This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By  




Dexxon Holdings Ltd.: Early Warning Report Issued Pursuant to National Instrument 62-103HomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets open in 15 mins.S&P Futures2,465.75-6.25 (-0.25%)Dow Futures21,703.00-40.00 (-0.18%)Nasdaq Futures5,878.75-30.75 (-0.52%)Dexxon Holdings Ltd.: Early Warning Report Issued Pursuant to National Instrument 62-103MarketwiredApril 6, 2015ReblogShareTweetShareMONTREAL, QUEBEC--(Marketwired - Apr 6, 2015) -  This press release is issued by Dexxon Holdings Ltd. (the "Offeror"), pursuant to the early warning requirements of applicable securities legislation and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues with respect to common shares ("Common Shares") in the capital of Cynapsus Therapeutics Inc. (the "Company").On March 30, 2015, the Offeror acquired ownership of 4,342,105 Common Shares in the capital of the Company in consideration for the payment by the Offeror of CAD$4,133,684 pursuant to and in accordance with the terms of a subscription agreement between the Offeror and the Company. The acquisition of the Offeror of the Common Shares resulted in the Offeror ownership of approximately 16% of all the issued and outstanding Common Shares on a non-fully diluted basis. Following completion of the purchase of the Common Shares, the Offeror owns or controls 18,104,647 Common Shares of the Company.The Common Shares were acquired by the Offeror through a private placement pursuant to Section 2.3 ("accredited investor") of National Instrument 45-16 - Prospectus and Registration Exemptions. The Common Shares were acquired at a price of CAD$0.95 per Common Share and are subject to a hold period, which will expire four months plus one day from the date of issue.The Common Shares were purchased by the Offeror for investment purposes. The Offeror may in the future take such actions in respect of its holdings in the Company as it may deem appropriate in light of the circumstances then existing, including the purchase of additional common shares, warrants or other securities of the Company through open market purchases or privately negotiated transactions or the sale of all or a portion of the Offeror's holdings in the open market or in privately negotiated transactions to one or more purchasers, subject in each case to applicable securities laws.A copy of the early warning report filed under applicable securities legislation in connection with the purchase of the Common Shares is available under the Company's profile on the SEDAR website at www.sedar.com.Dexxon Holdings Ltd.By: Dan OrenName: Dan OrenTitle: DirectorReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBoeing shares surge as it lifts outlook, boosts buybacksAFPEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredTrump’s unwitting legacy could be universal health coverageYahoo FinanceSean Hannity responds to claim he ran up a $42,000 tab at Trump's hotel after flying in a 70-year-old lobster from MaineBusiness InsiderConsumers, businesses lift U.S. economic growth in second quarterReutersZuckerberg Wife's Ambitious Secret Finally ExposedUNewz.MeSponsoredChesapeake Energy Corporation (CHK) Stock Is a BIG Buy Under $5InvestorPlaceTwitter is only famous now because of President Trump: NYSE traderYahoo Finance VideoGDP — What you need to know in markets on FridayYahoo FinanceThis Will Be In Everyone's Household By 2020Banyan HillSponsoredRepublicans warn Trump: No confirmation hearing for a Sessions replacement, and no recess appointment eitherBusiness InsiderStarbucks CEO: The Amazon-Whole Foods deal shows where retail is goingYahoo FinanceMattis was on vacation when Trump tweeted transgender ban, and he was reportedly 'appalled' by itBusiness InsiderA Penny-Crypto Miracle Making Some Americans RichAgora FinancialSponsoredWhy Snap Inc (SNAP) Stock Needs More Than Millennial Power to ThriveInvestorPlaceAmazon could be the first trillion dollar company: NYSE traderYahoo Finance VideoSenate 'skinny repeal' of Obamacare falls apart on Senate floor after McCain defectsDonovan: 3 Republicans and 48 Democrats let the American people down?!? Sorry Trump! But all I see is one incompetent idiot in the White House, who have let the American people down!!!Join the Conversation1 / 56.4k


















Dexxon Holdings Ltd. - Arbutus Biopharma Corporation Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsDexxon Holdings Ltd.Arbutus Biopharma Corporation (ABUS)Ten Percent OwnerRanked #13,901 out of 33,852 Insiders on TipRanksDexxon Holdings Ltd.'s PerformanceProfitable Transactions1 out of 3 profitable transactionsAverage  Return+2.9%Average return per transactionEach transaction is measured over a 1 Year3 Months1 Month period, and compared to No BenchmarkS&P 500Sector.How are Insiders Ranked? Insider Holdings 96.7% Axovant Sciences (AXON) 3.3% Arbutus Biopharma Corporation (ABUS)$2BSee the Top Stocks by Insiders > Insider RolesAxovant Sciences (AXON): Ten Percent OwnerArbutus Biopharma Corporation (ABUS): Ten Percent OwnerSee the Top 25 Corporate Insiders > Most Profitable Insider TradeStock: Axovant Sciences (AXON)Transaction Type: Informative BuyDates: Jul 13, 2016 - Jul 13, 2017Gain: +95.1%See the Latest Stocks Traded by Insiders > Dexxon Holdings Ltd.'s Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateABUSArbutus Biopharma CorporationTen Percent Owner$56,514,455Informative Buy(undisclosed)Jul 13, 2016AXONAxovant SciencesTen Percent Owner$1,680,235,855Informative Buy(undisclosed)Jul 13, 2016See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by
























